Source: Eur Respir Rev 2006; 15: 32-36
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Brusasco V.. Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur Respir Rev 2006; 15: 32-36

Member's Comments

No comment yet.

Related content which might interest you: Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease Source: Eur Respir J 2014; 44: 475-482 Year: 2014 Modulation of airway inflammation to prevent exacerbations of COPD Source: Eur Respir Rev 2005; 14: 78-82 Year: 2005 Respiratory muscles‘ function in chronic obstructive pulmonary disease patients treted with anticholinergic bronchodilator Source: Annual Congress 2009 - Respiratory physiology Year: 2009 Where current pharmacological therapies fall short in COPD: symptom control is not enough Source: Eur Respir Rev 2007; 16: 98-104 Year: 2007 Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 The role of bronchodilator treatment in the prevention of exacerbations of COPD Source: Eur Respir J 2012; 40: 1545-1554 Year: 2012 Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001 Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history Source: Eur Respir J 2011; 38: 553-560 Year: 2011 Pharmacological actions of statins: potential utility in COPD Source: Eur Respir Rev 2009; 18: 222-232 Year: 2009 The effect of short-acting beta-two-agonist on pulmonary rehabilitation in chronic obstructive pulmonary disease Source: Annual Congress 2009 - Pulmonary rehabilitation: extending the scope and benefit of rehabilitation for patients with chronic respiratory disease Year: 2009 Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) and COPD concomitant with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 521s Year: 2004 Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 427s Year: 2003 Effects of inhaled corticosteroids on airway inflammations of different types in patients with chronic obstructive pulmonary disease or asthma in stable phase Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Effects of long-acting bronchodilators on changes of inspiratory capacity by hyperventilation in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006 Acute effects of sildenafil in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Effects of different classes of bronchodilators on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease> Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Modern treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 60S-66S Year: 2001